Learning Objectives

  • Appraise the current role of systemic therapy in nonmetastatic prostate carcinoma (PC)
  • Select novel therapies for newly diagnosed metastatic PC
  • Evaluate the role of immunotherapy options with check point inhibitors in PC
  • Apply multitargeted kinase inhibitor, lenvatib in the treatment of metastatic renal cell carcinoma (RCC)
  • Examine optimal therapy with MET, AXL and VEGF receptor Inhibitor, canozantinib  in the treatment of metastatic RCC
  • Assess the immunotherapy options with novel PD-1/PD-L1 checkpoint inhibitors and targeted therapy combinations in patients with RCC
  • Review the genetic alterations in the molecular subtypes of urothelial bladder cancer (UBC)
  • Appraise the efficacy and safety of novel immunotherapy approaches with PD-1/PD-L1 antibodies in patients with UBC